The identified deviation concerns the active substance content. Administration of the medicine with an increased amount of topotecan may negatively affect treatment tolerability; haematological toxic effects are dose-dependent and may pose a health risk to the patient. Potential effects: haematological toxicity, complications of oncological treatment.
Download the app and stay informed
Get instant notifications about recalled products and protect your family.
Important Information
Do not use Hycamtin (Topotecan) products with batch numbers BCUN2 and BCUN3; if you possess these packs, contact a pharmacist or doctor.
The Chief Pharmaceutical Inspector prohibited the placement on the market throughout the country of Hycamtin (Topotecan) batches BCUN2 and BCUN3 and granted the decision immediate enforceability.
If you feel unwell after consuming this product, contact your doctor or call the poison control center.
FAQ
Related